High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action
Highlights
– In a 13-site prospective cohort (ACTG A5381–Hakim) across six PEPFAR-supported countries, initiation or switching to tenofovir–lamivudine–dolutegravir (TLD) yielded high viral suppression for people suppressed at switch and for ART-naive individuals.
– Participants who switched from failing protease-inhibitor regimens (VL >1000 copies/mL) had lower suppression and were the only group with emergent dolutegravir-associated mutations (G118R, R263K) in three individuals.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.